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therapy and the innate and adaptive defence mechanisms of the patient. Bioﬁlm infections are characterized by persisting and progressive
pathology due primarily to the inﬂammatory response surrounding the bioﬁlm. For this reason, many bioﬁlm infections may be difﬁcult to
diagnose and treat efﬁciently. It is the purpose of the guideline to bring the current knowledge of bioﬁlm diagnosis and therapy to the attention of
clinical microbiologists and infectious disease specialists. Selected hallmark bioﬁlm infections in tissues (e.g. cystic ﬁbrosis with chronic lung
infection, patients with chronic wound infections) or associated with devices (e.g. orthopaedic alloplastic devices, endotracheal tubes, intravenous
catheters, indwelling urinary catheters, tissue ﬁllers) are the main focus of the guideline, but experience gained from the bioﬁlm infections
included in the guideline may inspire similar work in other bioﬁlm infections. The clinical and laboratory parameters for diagnosing bioﬁlm
infections are outlined based on the patient’s history, signs and symptoms, microscopic ﬁndings, culture-based or culture-independent diagnostic
techniques and speciﬁc immune responses to identify microorganisms known to cause bioﬁlm infections. First, recommendations are given for
the collection of appropriate clinical samples, for reliable methods to speciﬁcally detect bioﬁlms, for the evaluation of antibody responses to
bioﬁlms, for antibiotic susceptibility testing and for improvement of laboratory reports of bioﬁlm ﬁndings in the clinical microbiology laboratory.
Second, recommendations are given for the prevention and treatment of bioﬁlm infections and for monitoring treatment effectiveness. Finally,
suggestions for future research are given to improve diagnosis and treatment of bioﬁlm infections.
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S2 Clinical Microbiology and Infection, Volume 21 Number S1, May 2015 CMIIntroductionBacteria and fungi occur as individual, free-ﬂoating (planktonic)
cells or clustered together in aggregates of cells (bioﬁlms). A
microbial bioﬁlm is ‘a structured consortium of microbial cells
surrounded by a self-produced polymer matrix’ [1] In addition
to microorganisms, components from the host, such as ﬁbrin,
platelets or immunoglobulins, may be integrated into the bio-
ﬁlm matrix. Both bacteria and fungi can cause bioﬁlm infections
and bioﬁlms may consist of one microorganism or be poly-
microbial [1–4]. Some bioﬁlms adhere to natural or artiﬁcial
surfaces in the host (including devices), while others may
consist of aggregates associated with but not directly adherent
to the surface (Fig. 1) [3,4]. Importantly, bioﬁlms are charac-
terized by physiological and biochemical gradients (nutrients,
oxygen, growth rate, genetics) from the surface to the deeper
layers of the aggregated structure. Bioﬁlm-growing microor-
ganisms express different speciﬁc properties compared with
planktonically (= non-aggregated) growing microorganisms [4].
The observation of aggregated microbes surrounded by a self-
produced matrix adhering to surfaces or located in tissues or
secretions is as old as microbiology since both Leeuwenhoek
and Pasteur described the phenomenon [5]. In environmental
and technical microbiology, bioﬁlms were already shown,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect80–90 years ago, to be important for biofouling on submerged
surfaces, e.g. ships. The concept of bioﬁlm infections and their
importance in medicine is, however, less than 40 years old and
started by Høiby’s observations of heaps of Pseudomonas aer-
uginosa cells in sputum and lung tissue from chronically infected
cystic ﬁbrosis (CF) patients and Jendresen’s observations of
acquired dental pellicles [5]. The term bioﬁlm was introduced
into medicine in 1985 by Costerton [5]. During the following
decades it became obvious, that bioﬁlm infections are wide-
spread in medicine and odontology, and their importance is
now generally accepted [5].
Bioﬁlms typically cause chronic infections, which means that
the infections persist despite apparently adequate antibiotic
therapy and the host’s innate and adaptive defence mechanisms.
Chronic infections are characterized by persistent and pro-
gressing pathology, mainly due to the inﬂammatory response
surrounding the bioﬁlm [6]. This also means that persisting local
inﬂammation is the only common feature of various bioﬁlm
infections, whereas other signs and symptoms depend on the
impairment— if any—of the function of the organ/foreign body
infected by a microbial bioﬁlm [5,6]. The inﬂammatory cells
dominating the persisting bioﬁlm infection may be poly-
morphonuclear neutrophil leucocytes or mononuclear cells
depending on whether the predominating immune response toFIG. 1. Typical bioﬁlm infections (3)
(reproduced with permission).
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
CMI Høiby et al. ESCMID Bioﬁlm guideline S3the microbes of the bioﬁlm is T helper type 2 (antibodies) or T
helper type 1 (cell-mediated) polarized [5,8]. Many bioﬁlm in-
fections are difﬁcult to diagnose and treat and currently no
guidelines exist to help clinicians and clinical microbiologists
with these infections.
Most microorganisms in the environment grow as bioﬁlms in
order to be protected against the hostile environment [7].
Traditionally, clinical microbiology laboratories have focused on
culturing and testing planktonically (= non-aggregated) growing
microorganisms and have reported the susceptibility to various
antibiotics and antiseptics under planktonic growth conditions.
Microorganisms in the bioﬁlm mode of growth, however, cause
chronic infections in tissues and on the surface of medical de-
vices. The clinical implications of microorganisms growing as
bioﬁlms are that they may be more difﬁcult to recover from
clinical samples, and that they are physiologically much moreFIG. 2. Bioﬁlm causing tissue infection. Bioﬁlms of P. aeruginosa from sputum o
P. aeruginosa speciﬁc probe (f, g). The bacteria and the matrix are visible. A
morphonuclear leukocytes (arrows), b & c: with a few leukocytes within th
planktonic bakteria (arrow). Magniﬁcation x 1000 [8] (reproduced with perm
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologresistant to the effects of antibiotics and disinfectants [6].
Moreover, antibiotic therapy based on susceptibility testing of
planktonic microorganisms may be associated with treatment
failure or recurrence of the infection. It is the purpose of the
guideline to bring the current knowledge of bioﬁlm diagnosis
and therapeutic practice to the attention of clinical microbiol-
ogists and infectious disease specialists.
The guideline addresses the diagnosis and treatment of bio-
ﬁlm infections. Such infections can be classiﬁed into those
where bioﬁlms are found in the tissue/mucus and not associated
with foreign bodies and those where bioﬁlms are adherent to
foreign bodies [3] (Fig. 1). The ﬁrst group includes CF patients
with chronic lung infections (Figs. 2, 3) and patients with
chronic wound infections (Fig. 4), where the bioﬁlms are found
in the tissue and also in sputum of patients with CF [8–10]. The
second group includes infections related to bioﬁlms colonizingf cystic ﬁbrosis patients. Gram-staining (a-e), PNA-FISH staining with a
diversity of shapes of the bioﬁlms are seen, a: with surrounding poly-
e alginate matrix, d: with channel-like holes (arrow), e: with liberated
ission).
y and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
FIG. 3. P. aeruginosa from sputum of a cystic ﬁbrosis patient. Mucoid
(large) and nonmucoid (small) colonies. The mucoid variant over-
produces alginate which is the matrix in the P. aeruginosa bioﬁlm in
the respiratory tract of cystic ﬁbrosis patients. Mucoid colonies are only
found in patients with chronic bioﬁlm infection and alginate from
mucoid colonies is therefore a bioﬁlm-speciﬁc antigen.
FIG. 4. Bioﬁlm causing tissue infection. Bioﬁlm of S. aureus in a chronic
wound. The bacteria were identiﬁed by a speciﬁc PNA-FISH probe
(green stain) and the host cells visualised by DAPI (blue stain). Magni-
ﬁcation x 1000 [9] (reproduced with persission).
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Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectdevices implanted inside the body or forming a connection
between an inner or outer surface of the body where a normal
microbial ﬂora is present and a sterile anatomical compartment
inside the body (Figs. 1, 5–9; Table 1). This group includes
infections associated with orthopaedic alloplastic devices [11],
endotracheal tubes [12–15], intravenous catheters [16],
indwelling urinary catheters or urethral stents [17,18] and tis-
sue ﬁllers [19,20] including, but not restricted to, breast im-
plants [21]. Many other bioﬁlm infections are the subject of
existing guidelines (e.g. endocarditis, otitis media, chronic
sinusitis, biliary stents, shunts, contact lenses, voice prostheses,
dialysis catheters, dental, intrauterine devices, artiﬁcial hearts,
prosthetic valves). However, the present guideline will focus on
the bioﬁlm infections outlined above. The target professionals
are clinical microbiologists and infectious disease specialists
involved in diagnosis and treatment of bioﬁlm infections.
The overall burden of bioﬁlm infections is signiﬁcant [22].
For example, among the >60 000 CF patients in developed
western countries, nearly 80% will develop a chronic bioﬁlm
lung (and paranasal sinus) infection. For patients with chronic
wound infections (1–2% of western populations) more than
60% have been shown to involve bioﬁlms. For all patients with
orthopaedic alloplastic device, 0.5–2% will develop an infection
within the ﬁrst two postoperative years [23–25]. Additionally,
among patients with intravenous catheters, 5 per 1000 catheter
days in the intensive care unit will develop catheter-related
bloodstream infections (CR-BSI). The development of bioﬁlm
on the surface of endotracheal tubes (ETT) is related to the
development of ventilator-associated pneumonia (VAP), which
occurs in 9–27% of all intubated patients [26]. The rates for
patients with indwelling urinary catheters are even higher
because more than 50% of inserted catheters become colo-
nized within the ﬁrst 10–14 days of insertion [27,28] and for
patients with tissue ﬁllers where 1–2% experience adverse
events of which almost all arise from bioﬁlm infections. Post-
mastectomy tissue-expander infections occur in 2–24% of pa-
tients [29].
For many of the above infections—with the possible
exception of CF—there are controversies and uncertainties
concerning both the diagnosis of bioﬁlm infections and treat-
ment or prophylactic approaches using antibiotics. These issues
have been discussed in depth in all six American Society for
Microbiology and three European Society for Clinical Micro-
biology and Infectious Diseases (ESCMID) conferences on
bioﬁlm infections from 1996 to 2013. These conferences and
discussions about bioﬁlm infections, as well as numerous text-
books, emphasize that in clinical settings the diagnosis and
treatment of bioﬁlm infections is inconsistent. This calls atten-
tion to the need for the development of evidence-based
guidelines.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
FIG. 5. Bioﬁlm causing device-related infection and as the focus for systemic infection. A bioﬁlm is located on a pancreatic-biliary stent from a 57 years old
man. The bioﬁlm was the focus of recurrent sepsis with E. coli (July 21-2003) where he was treated with adequate (planktonic susceptibility testing)
antibiotics for 5 days and with the same E. coli strain and K. oxytoca (August 12, 2003) where he succumbed in spite of antibiotic treatment. Autopsy on
August 14, 2003 showed growth from the bioﬁlm of E. coli, K. oxytoca (same Pulsed Field Gel Electrophoresis (PFGE) type as isolated from the blood
previously) and E. faecium which was not isolated from the blood. The ﬁgure with red arrows shows the stent held above a 9 cm petri dish with blood
agar (upper left), the stent which has been opened (right), Methylene- and Gram-stained smears (magniﬁcation x 1000) and results of culture and
susceptibility testing and PFGE. (111)(Reproduced with permission).
CMI Høiby et al. ESCMID Bioﬁlm guideline S5For some of the bioﬁlm infections mentioned above, e.g. CF
[30–34], intravenous catheters [16], indwelling urinary cathe-
ters or urethral stents [17,18,35,36] and periprosthetic joint
infections [37,38], there is sufﬁcient scientiﬁc evidence of good
quality to allow development of a guideline document. For
others such as chronic wounds [9,39,40] and tissue ﬁllers [19],
there is good quality evidence for diagnostic approaches but
probably not yet for therapy. As for VAP associated with ETT
bioﬁlm, in all available studies [12,14,41,42], the ETT bioﬁlm has
been evaluated following extubation. Hence, no reliable
methods are currently available to detect ETT bioﬁlm while the
patient remains on invasive mechanical ventilation. Conversely,
a few preventive and therapeutic strategies to reduce ETT
bioﬁlm formation and VAP have been tested in clinical settings
[43–46].
The expert panel has completed a systematic review of the
literature within the speciﬁc areas outlined above and prepared
this document based on the systematic reviews including key
questions concerning diagnosis, prophylaxis and treatment ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologbioﬁlm infections and has evaluated the strength of the rec-
ommendations and quality of evidence (Tables 2 and 3).Diagnosis of Bioﬁlm InfectionsGenerally: Bioﬁlms are small in vivo, in tissues 4–200 μm, on
foreign bodies 5–1200 μm (Table 4) [10]. Therefore, the
search for bioﬁlms in clinical samples may be difﬁcult and time
consuming, and may result in false-negative results if the sam-
ples are not representative of the focus of the bioﬁlm infection.
Bioﬁlms can be released from artiﬁcial surfaces by sonication of
ﬂuids containing the sample [47].
Q1-1 Which type of samples should be sent to the
clinical microbiological laboratory to detect bioﬁlm
infections?
CF with chronic lung infections. A major problem in this type of
infection is contamination of lower respiratory secretions withy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
FIG. 6. Bioﬁlm causing device-related infection. PNA-FISH micrograph of
catheter bioﬁlm. Material scraped from a urinary catheter was hybrid-
ized with a universal bacterial probe (UUBmix) and an Enter-
obacteriaceae probe. Single cells and clusters of enterobacteria are
visible in the bioﬁlm. The large green background indicates unspeciﬁc
binding of the EUBmix probe to the bioﬁlm. E. faecalis and E. coli were
isolated from the catheter tip by culture (82)(reproduced with
permission).
FIG. 7. Bioﬁlm causing device-related infection. Three-dimensional
confocal laser scanning microscopy of a biopsy from a grade 3 reac-
tion following gel injection into the cheek 2 years previously. A PNA-
FISH universal bacterial probe was used to visualize aggregates of
bacteria (small red micropheres; arrows). The large blue dots represent
DAPI nuclear counterstain of the predominating mononuclear cell types
in these lessions. S. epidermidis had been identiﬁed by 16S rRNA gene
sequencing. Magniﬁcation x 1000 (19)(reproduced with permission).
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Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectthe normal oropharyngeal ﬂora, particularly since members of
the normal ﬂora (e.g. Haemophilus inﬂuenzae, Streptococcus
pneumoniae, Staphylococcus aureus, Moraxella catarrhalis) are
common lung pathogens in CF [48]. Representative material
originating from lower airways (sputum, protected samples
through bronchoalveolar lavage, endolaryngeal suction (from
small children), induced sputum) should be sent to the clinical
microbiological laboratory (CML) [30–34] (AII).
Patients with chronic wound infection. Biopsy tissues are consid-
ered the most reliable samples to reveal bioﬁlm in wounds. The
use of swabs to collect bioﬁlm samples from the wound surface
is considered an inadequate method (DII), due to contamination
from the skin ﬂora, the strong adherence of bioﬁlm to the host
epithelium and the growth of anaerobes in the deep tissues. If a
moderate to severe soft tissue infection is suspected and a
wound is present, a soft tissue sample from the base of the
debrided wound should be examined. If this cannot be ob-
tained, a superﬁcial swab may provide useful information on the
choice of antibiotic therapy [49,50] (AII).
Patients with infections related to an orthopaedic alloplastic device
(e.g. an artiﬁcial joint). If an orthopaedic implant-associated
infection is suspected, synovial ﬂuid should be sampled for
cell counts and microbiological work-up. If the results suggest
or conﬁrm infection, debridement surgery is indicated (AIII).
Intraoperative sampling includes biopsies from representative
peri-implant tissue and removal of the device/prosthesis or
modular parts of it (e.g. inlay, screws). This foreign material
should be submitted for sonication to liberate the bioﬁlm
before being cultured in the CML [51] (BII). The Clinical
Practice Guidelines on Diagnosis and Management of Prosthetic
Joint Infection by the Infectious Diseases Society of America
[37] recommend sampling of three to six biopsies. The pres-
ence of at least two positive culture specimens with an identical
microorganism conﬁrms periprosthetic joint infection [52–56].
The biopsies should be as large as possible (up to 1 cm3) and
labelled and paired with the culture specimens to differentiate
contamination from infection [57–60] (AIII).
Patients with endotracheal tube bioﬁlm, VAP. There is a lack of
validated methods to monitor bioﬁlm formation within the ETT
and to distinctly recognize its role in the development of VAP.
First, in mechanically ventilated patients who develop VAP,
bioﬁlm within the ETT can be either the primary source of the
infection or merely a concomitant colonized site. Second,
respiratory secretions often accrue within the ETT; as a result,
bioﬁlm and respiratory secretions constitute a complex
mixture that is difﬁcult to characterize. The presence of sessile
pathogens adherent to the ETT surface may be overestimated,
because of the vast concentration of planktonic pathogensious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
FIG. 8. Microscopy studies of the endotracheal tube of a pig invasively mechanically ventilated for 72 hours, following oropharyngeal challenge with
Pseudomonas aeruginosa (Li Bassi et al. Anesthesiology, accepted, 2013). a: Light microscopy of bioﬁlm and respiratory secretions retrieved from the
inner surface of the endotracheal tube (magniﬁcation x1000, oil immersion objective lens). Bioﬁlm/secretions were spread on a glass slide, and stained
with Congo Red and Crystal Violet for light microscopic studies [63]. The black arrow indicates an aggregate of rod-shaped bacteria; microorganisms
stain as purple, and the bioﬁlm exopolysaccharide stains as pink. b: Confocal laser scanning micrograph of the internal surface of the endotracheal tube
(magniﬁcation x250). The sample was stained with BacLight Live/Dead (Invitrogen, Barcelona, Spain). The white arrow depicts the endotracheal tube
outer surface. A fully mature bioﬁlm adherent to the endotracheal tube is shown and rod-shaped bacteria are embedded within the bioﬁlm matrix. c:
Scanning electron micrograph frontal-view of the internal surface of the endotracheal tube (magniﬁcation x1500) (Fernández-Barat et al. Crit Care Med
2012; 40: 2385-95)( Berra et al. Anesthesiology 2004; 100: 1446-56). Note presence of stage IV bioﬁlm, characterized by multiple rodshaped bacteria
embedded within an extracellular polymeric substance, as depicted by the white arrow. (Micrographs kindly provided by Laia Fernandez-Barat and Eli
Aguilera Xiol, Hospital Clinic-CIBERES, Barcelona, Spain.)
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studies [11,14] have found matching pathogens in both the ETT
bioﬁlm and secretions accrued within the airways/ETT in
56–70% of patients with VAP. A clinical guideline on the
diagnosis of VAP [26] recommends that samples of lower
respiratory tract secretions should be obtained and cultured
from all patients with clinical suspicion of VAP, before change of
antibiotic therapy, to identify the aetiology of VAP (AIII). Res-
piratory secretions can be obtained through endotracheal
aspirate, bronchoalveolar lavage, or protected specimen brushFIG. 9. Field emission scanning electron micrograph of a polymicrobial
bioﬁlm developed in the lumen of a Foley catheter removed from a
patient affected by a catheter-associated urinary tract infection. The
species identiﬁed by culture methods were Acinetobacter baumannii,
Enterococcus faecalis and Escherichia coli (G. Donelli).
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologdepending on the situation and possibilities. In addition to these
sampling procedures, in patients with clinical suspicion of ETT
bioﬁlm VAP, mucus from within the ETT can be aspirated and
cultured to identify ETT pathogens in ETT bioﬁlms that may
have caused VAP (BII). This is not necessary for the diagnosis of
the aetiology of VAP but may lead to a decision to replace the
ETT. Devices serving to remove secretions and bioﬁlm from
the inner lumen of ETT, i.e. the Mucus Shaver (described in
Q2-2) [43,61,62], can be employed to dislodge bioﬁlm and
identify the aetiology of ETT bioﬁlm VAP (BIII). Mucus and
bioﬁlm retrieved from the inner surface of the ETT can be
processed in the CML for microscopic examination of the
presence of bacterial aggregates and bioﬁlm on the ETT luminalTABLE 1. Natural and pathogenic bioﬁlms on human tissue
and foreign bodies
Organ/anatomic
compartment A
with normal ﬂora
(microbiome)
Connection
[may be via
a foreign body]
Organ/anatomic
compartment B
without normal ﬂora
(microbiome)
Skin -> Blood, peritoneum
Pharynx -> Bronchi, lungs
Duodenum -> Bile tract, pancreas
Urethra -> Bladder
Vagina -> Uterus
Air in operating room,
skin ﬂoraa
-> Alloplastic material,
neurosurgical shunt
No symptoms -> Pathology
Reproduced from ref. [1] with permission.
aMost frequently coagulase negative staphylococci and Propionibacteria, which exist
as bioﬁlms on detached epidermal cells.
y and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
TABLE 2. Deﬁnition of strength and quality of recommendations [196]
S8 Clinical Microbiology and Infection, Volume 21 Number S1, May 2015 CMIwall (Fig. 8) [63,64] (BIII). After extubation, the ETT inner
surface can also be processed in the CML for microscopic
examination of the presence of bioﬁlms [43,64–66] (Fig. 8)
(BIII).
Patients with vascular catheters. If the catheter is removed, the
catheter tip (3 to 4 cm distal) should be sent to the CML for
quantitative or semi-quantitative culture [16,67,68] (AII). In
cases of totally implantable venous access port-related infection
(e.g. Port-a-Cath®), also send the reservoir and/or the port to
the CML [69,70] (AII). In cases of signs of local infection (tunnel
or port-pocket infection), send aseptically removed materialClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectsurrounding the port or tunnelled catheter, such as purulent
ﬂuid or necrotic skin, ideally during the surgical procedure, to
reduce the risk of false-positive results [71,72]. Superﬁcial
swabs of skin and catheter hubs are associated with a high
negative predictive value for short-term as well as long-term
catheters [73,74] (BII).
If catheter-related infection is suspected and the catheter is
still in situ, send paired blood cultures from the vascular cath-
eter and peripheral blood taken simultaneously. Two types of
blood cultures can be used: qualitative blood cultures with data
of the time to positivity (TTP) [73,75–77] (AII) and quantitative
blood cultures [73,78] (AII). These two methods areious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
TABLE 3. General features of clinical and laboratory
indications for diagnosis of bioﬁlm infectionsa
 Clinical signs of infection e.g. the classical but
frequently low-grade inﬂammatory reactions tumor,
rubor, dolor, loss of function and sometimes low-grade
fever
 Medical history of bioﬁlm-predisposing condition (e.g.
implanted medical device, cystic ﬁbrosis)
 Persisting infection lasting >7 days (this is unspeciﬁc, and
other reasons are frequent such as resistance to the
antibiotics used)
 Failure of antibiotic treatment and recurrence of the
infection (particularly if evidence is provided that the
same organism is responsible on multiple time
points)—typing of the pathogen
 Documented evidence/history of antibiotic failure
 Evidence of systemic signs and symptoms of infection
that resolve with antibiotic therapy, only to recur after
therapy has ceased.
Microbiological diagnostics:
 Microscopic evidence from ﬂuid/tissue samples obtained
from the focus of the suspected infection
o Microscopy revealing the presence of microbial
aggregates and bioﬁlm structure (smear or ﬂuid
sample, but ideally from tissue sample if possible)
o Microscopy revealing evidence of microbial aggregates
co-localized with inﬂammatory cells
o Microbiological evidence of aggregated
microorganisms consistent with infectious aetiology
 Positive culture/non-culture-based techniques (PCR) of
ﬂuid or tissue sample
o Culture-based identiﬁcation of microbial pathogens
(MALDI-TOF)
o Presence of mucoid colonies or small colony variants
of P. aeruginosa in culture positive samples—which
may indicate antibiotic recalcitrance)
o PCR, quantitative PCR or multiplex PCR positive
results for pathogen associated with infection (e.g.
Staphylococcus aureus with implant, Pseudomonas
aeruginosa with cystic ﬁbrosis)
o ﬂuorescence in situ hybridization positive results for
known pathogen showing aggregated microoganisms
o Non-culture-based identiﬁcation of microbial
pathogen (pyrosequencing, next-generation
sequencing).
 Speciﬁc immune response to identiﬁed
microorganism—(e.g. P. aeruginosa antigens in cystic
ﬁbrosis patients) if the bioﬁlm infection has been present
for more than 2 weeks.
Modiﬁed from ref. [1].
aSpeciﬁc features depend on possible impairment of the function of the organ/
foreign body involved.
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Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologconsidered equal, but TTP is the most convenient in the routine
CML because the TTP is recorded by modern blood culture
systems.
Patients with indwelling urinary catheters or urethral stents. The
simplest way to reveal catheter-associated urinary tract in-
fections is to collect urine samples from the catheter (CI),
although this method can lead to false-negative results in
bioﬁlm-positive microorganisms in 50–64% [36,79,80].
Removed catheters can also be analysed in the CML by mi-
croscopy and by cultivation or culture-independent techniques,
preferably after sonication to investigate microbial diversity.TABLE 4. Bioﬁlm size in chronic infections in otherwise sterile
parts of the human bodya (See also Table 3)
Bioﬁlm
demonstrated in
Visualization
method
Approximate
diameter Reference
Lung infections (CF) Light microscopy ~4–8 μm [197]
Light microscopy ~5–100 μm [198]
FISH ~5–100 μm [8]
FISH ~5–50 μm [199]
Chronic wounds FISH ~5–200 μm [40]
FISH ~5–100 μm [9]
Light and electron
microscopy
~35–55 μm [39]
Soft tissue ﬁllers FISH ~5–25 μm [20]
Otitis media FISH ~15–25 μm [200]
FISH ~10–80 μm [201]
FISH ~4–40 μm [202]
Implant-associated Electron microscopy ~500 μm [203]
FISH ~50 μm [204]
Electron microscopy ~5–15 μm [205]
FISH ~5–30 μm [206]
Catheter- and
shunt-associated
Electron microscopy ~5–1000 μm [207]
Electron microscopy ~20–500 μm [208]
Fluorescence
microscopy
~20–1200 μm [209]
FISH and electron
microscopy
>1000 μm [210]
Chronic
osteomyelitis
Electron microscopy ~25 μm [211]
Electron microscopy ~25 μm [212]
Light and electron
microscopy
~5–50 μm [213]
Chronic
rhinosinusitis
Electron microscopy ~5–30 μm [214]
Fluorescence
microscopy
~5–20 μm [215]
Contact lenses Electron microscopy ~50–100 μm [216]
Abbreviations: CF, cystic ﬁbrosis; FISH, ﬂuorescence in situ hybridization.
aThe bioﬁlm aggregate size was estimated by measuring the longest diameter or
length directly on the micrograph images in the source articles. (adapted from
ref. [10]).
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TABLE 5. Diagnostic use of three different anti-Pseudomonas
antibody methods to detect chronic Pseudomonas aeruginosa
bioﬁlm infection in Scandinavian cystic ﬁbrosis patients [103]
Crossed
immune-
electrophoresis
(95% CI)
Pseudomonas-
CF-IgG
ELISA (95% CI)
Exotoxin A
ELISA
(95% CI)
Speciﬁcity 89% (86–92) 83% (78–87) 89% (85–92)
Sensitivity 96% (93–98) 97% (94–99) 93% (89–96)
Positive predictive value 87% (82–90) 80% (75–84) 86% (81–90)
Negative predictive value 97% (95–99) 98% (95–99) 95% (92–97)
Positive predictive value
after patients with other
Gram-negative infections
were excluded
93% (89–95) 85% (80–89) 88% (84–92)
Negative predictive value
after patients with other
Gram-negative infections
were excluded
97% (95–99) 97% (94–99) 95% (92–97)
S10 Clinical Microbiology and Infection, Volume 21 Number S1, May 2015 CMIThis approach ensures the detection of bioﬁlm infection
because of isolation of only the adherent bacteria [36,80–85]
(AII).
Patients with infections connected to tissue ﬁllers e.g. breast implants.
Removed material and contiguous material (BIII).
Q1-2 Which methods should be used in the CML to
detect bioﬁlms in the samples?
Detection of bioﬁlms in the samples requires that microscopy
should show evidence of an infective process, such as the
presence of leucocytes, and that the microorganisms present
are demonstrated to be microbial aggregates embedded in an
apparently self-produced matrix distinct from the surrounding
tissue or secretion. Microscopic analysis can be done using
routine light microscopy and routine staining methods including
Gram stain, which stains both tissue or mucus and the in-
ﬂammatory cells, bacteria and the bioﬁlm matrix [8] (AII).
Techniques such as confocal laser scanning microscopy and
scanning electron microscopy are the most appropriate to
reveal bioﬁlms in biopsies but they are not available for routine
diagnostic work in CML [86] (BIII).
Speciﬁc microscopic identiﬁcation of the bioﬁlm microor-
ganisms in samples (biopsies or swabs) can be done by means of
species-speciﬁc ﬂuorescence in situ hybridization probes and
ﬂuorescence microscopy [8] (AII), whereas conventional cul-
ture methods or culture-independent methods based on PCR
techniques (16S rRNA gene ampliﬁcation, denaturant gradient
gel electrophoresis, bacterial tag-encoded FLX amplicon pyro-
sequencing) [25,59] cannot discriminate between planktonic
and bioﬁlm-growing bacteria [82,83–86].
Furthermore, in clinical samples planktonic microorganisms
are released from bioﬁlms and microorganisms may thereforeClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectbe found in both forms. Release of microorganisms from bio-
ﬁlms may be achieved by imprint (and visualized by Gram stain),
rolling (the Maki method), and semi-quantitative reporting of
the number of colony-forming units (CFU) obtained, or by
scraping, whirly-mixing, vortexing and/or sonication (Brun–
Buisson method) [57,80,87–89]. Crushing or tissue homoge-
nization may be necessary if the bioﬁlm is situated on the
surface of a foreign body or in a bone or a cardiac valve (AII).
Some microorganisms in bioﬁlms may be viable but non-
culturable [90] when using routine media. In that case
culture-independent methods should be used [91,92] (BII). In
areas of the body where a normal ﬂora (microbiome) is present
(in the mouth, pharynx, gut, skin) (Table 1), special pre-
cautions—such as washing or irrigating the area—should be
taken to minimize contamination from the normal ﬂora. Since
culture or culture-independent techniques (e.g. PCR) cannot
distinguish between bioﬁlm-growing and planktonic microor-
ganisms, the identiﬁcation of bioﬁlms relies on microscopic
detection of microbial aggregates located in a matrix. It should
be noted that low or non-pathogenic members of the normal
ﬂora may be important bioﬁlm producers (e.g. Staphylococcus
epidermidis bioﬁlms on intravenous lines or on orthopaedic
alloplastic material). Ideally the results of microscopy and cul-
ture should be quantitative or semi-quantitative and organisms
should be identiﬁed to the species level to help discriminate
between contaminants from the normal ﬂora and infecting
microorganisms, regardless of whether they have previously
been associated with bioﬁlm infections.
Practice points. In the case of tubes, urinary tract catheters and
vascular catheters, (intravenous lines) bioﬁlms may be located
on both outer and inner surfaces.
For diagnosis of catheter-related infection. Microscopy of Gram-
stained imprints from, for example, tips can be used as rapid
detection of bioﬁlm infections [16] (AII).
The culture of the catheter tip can be made with a quanti-
tative or a semi-quantitative method. For quantitative culture,
the tip is sonicated or vortexed in a 1-mL solution with a sig-
niﬁcant threshold of 103 CFU/mL to distinguish between
colonization and contamination (Brun–Buisson method) (AII).
For the semi-quantitative method, the catheter tip is rolled on
an agar plate (Roll-plate method, also called the Maki method).
The threshold is 15 CFU [68] (AII). A meta-analysis published
in 1997 seemed to favour the quantitative method [93] but a
more recent paper stated that they could be considered equal
for the diagnosis of tunnelled catheter-related infections [94].
Current Infectious Diseases Society of America guidelines
consider that both methods can be used [16] and we came to
the same conclusion (AII).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
FIG. 10. Confocal laser scanning microscopy of a green-ﬂuorescent-
protein-tagged Candida albicans bioﬁlm. Magniﬁcation x1000 (C.
Imbert).
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blood cultures from a catheter and a peripheral vein with one
of the two following differential criteria indicate bioﬁlm infec-
tion: 1) TTP: 2 h earlier growth in the bottle with blood
drawn from central venous catheter (CVC) [73,75,76] (AII); 2)
quantitative blood culture with various thresholds published so
far [73,78] (AII). Infectious Diseases Society of America
guidelines propose the following threshold: a three-fold greater
colony count in the blood drawn from CVC than in blood
drawn from peripheral vein (AII) [16].
In case of totally implantable venous access port-related infection
(e.g. Port-a-Cath®). Peripheral blood culture associated with a
positive culture of the catheter tip (in situ located in the
bloodstream) or the subcutaneous septum (to be penetrated by
needles for injection of drugs into the catheter) [69,70] (AII).
There is no consensus regarding methods to culture the port
reservoir or septum. The following methods have been pro-
posed: an adapted Brun–Buisson method of the septum after
removal, the sampling of any macroscopic debris or clots
present after septum removal or the swabbing of the internal
surface of the port [72,74] (BIII). Some authors also propose
the injection of sterile saline inside the port to recover ﬂuid,
which is subsequently cultured [95]. No data are available to say
which method is more accurate. Recently, a paper suggested
that the best strategy was to combine catheter tip culture, port
sonication ﬂuid and internal surface bioﬁlm cultures [96].
Candida bioﬁlms. Traditional techniques require device removal
followed by culture or microscopy of a catheter segment.
Catheter-sparing diagnostic tests include paired quantitative
blood cultures, differential time to positivity of paired blood
culture, catheter-drawn quantitative blood cultures, acridine
orange leucocyte cytospin with or without Gram stain [97].
These in situ techniques avoid catheter removal strictly for
diagnostic purposes [16,98]. Diagnosis of Candida bioﬁlm
(Fig. 10) using microbiological techniques poses major obsta-
cles. Compared with many bacterial pathogens, blood cultures
are not consistently positive for Candida, even in the case of
systemic disease and previous antifungal therapy may also
signiﬁcantly impact the sensitivity of microbiological tech-
niques, [99]. Furthermore, paired blood cultures have been
poorly studied for fungal pathogens and are less accurate than
for bacterial infection [99]. Sonication-vortexing recovers
signiﬁcantly more bioﬁlm Candida CFU than brushing [99,100].
TTP of Candida species in culture bottles of peripheral blood
may be a useful tool in the evaluation of patients with candi-
daemia who have an indwelling CVC, since TTP was shorter
for deﬁnite catheter-related candidaemia (17.3 ± 2 h) than for
candidaemia from other sources (38.2 ± 3 h). A TTP cut-off ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiolog30 h was 100% sensitive and 51.4% speciﬁc for catheter-
related candidaemia. So TTP in peripheral blood may be a
sensitive, although non-speciﬁc, marker for catheter-related
candidaemia and TTP of more than 30 h may help to
exclude an intravascular catheter as the possible source of
candidaemia (CIII) [101,102]. The number of positive periph-
eral blood cultures also seems to be a promising diagnostic
tool to diagnose catheter-related candidaemia without directly
removing the catheter [99].
In case of bioﬁlm urinary tract infections in patients with indwelling
urinary catheters or stents. Freshly obtained urine from the
bladder should be processed as in non-catheterized patients
bearing in mind that this procedure gives more than 50% false-
negative results in these patients. Examination of removed
catheters or stents is necessary for detection of bioﬁlm infec-
tion; however, the routine examination of removed urinary
catheters or stents is not recommended.
Bioﬁlm-speciﬁc microbial phenotypes. These have rarely been
described with the exception of mucoid (and maybe small
colony variant) P. aeruginosa in CF (Fig. 3) [8,103]. This mucoid,
slimy component is the polysaccharide alginate; however, no
validated commercial methods to detect alginate in samples
(e.g. sputum) are currently available. We recommend that
growth of mucoid P. aeruginosa from clinical samples indicates
the presence of bioﬁlm infection and the mucoid phenotype
should therefore be reported to the clinicians [8,103] (AI).y and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
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markers of any value to detect bioﬁlm infections?
Signiﬁcantly elevated levels of IgG antibodies against crude or pu-
riﬁed antigens from P. aeruginosa antigens measured by various
methods including ELISA, these elevated levels are diagnostic
for P. aeruginosa bioﬁlm infections in CF patients and such tests
are commercially available and have been validated (Table 5)
[103] and are recommended for detection of P. aeruginosa
bioﬁlm infection in CF patients (AI). Likewise, signiﬁcantly
elevated antibodies against antigens from other bacteria causing
bioﬁlm infections in CF patients (e.g. Burkholderia cepacia
complex, Achromobacter xylosoxidans, Stenotrophomonas malto-
philia) have been reported, but no commercial tests are avail-
able. Some of the P. aeruginosa antibody tests have also been
used in non-CF patients with chronic P. aeruginosa infections
caused by mucoid phenotypes that also show signiﬁcantly
elevated antibody responses. IgM antibody response against
bioﬁlm-speciﬁc polysaccharide antigen in S. aureus and
S. epidermidis alloplastic-related infections has also been re-
ported [104,105] and can be recommended (BII). An elevated
IgG and especially secretory IgA antibody response [106] with
simultaneous negative cultures may encourage a search for
hidden foci (e.g. paranasal sinuses). This is done by means of
further samplings by more invasive techniques (e.g. bron-
choalveolar lavage or nasal irrigation) and use of culture-
independent techniques (e.g. 16S rRNA gene PCR) to detect
microorganisms suppressed/killed by ongoing antibiotic therapy
[107] and this is recommended (AII). There are however, no
widely available antibody measurement methods or inﬂamma-
tory markers speciﬁc for bioﬁlm infections.
Inﬂammatory markers. The non-speciﬁc inﬂammatory markers
(C-reactive protein, procalcitonin, erythrocyte sedimentation
rate, white blood cells), or various cytokines cannot distinguish
between infections caused by planktonic cells and bioﬁlm in-
fections (DIII) [108,109].
Q1-4 How should the CML report to the clinician that
bioﬁlms have been detected?
Since an antibiotic treatment regimen for acute infectionsmay fail
in the case of bioﬁlm infections and since foreign bodies associ-
ated with bioﬁlm infections may have to be removed/replaced or
the infection suppressed by antimicrobial treatment, it is
important that the CML reports include whether microbial bio-
ﬁlms have been detected in patients’ samples. It is important to
note that identiﬁcation of the presence of bioﬁlms may be time
consuming and needs to take into account the clinical condition of
the patient so any clinician suspecting an infection due to a bioﬁlm
should contact the CML to ensure that appropriate diagnostic
methods are employed. If a microbial bioﬁlm is detected byClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectmicroscopy it may be reported using descriptive terms e.g. ‘Mi-
croscopy shows Gram-negative rods in bioﬁlm-like structures’
(Figs 2, 4–10) and the species should be reported if speciﬁc
ﬂuorescence in situ hybridization probes have been used (Fig. 2)
(AIII). In other cases where microbial bioﬁlm infection is sus-
pected (e.g. culture positive or PCR positive only following son-
ication or after scraping, rolling etc.) the ﬁndingsmay be reported
as ‘Growth of/PCR-detected microorganisms possibly from a
bioﬁlm infection’. Additionally the CML may offer assistance to
the clinician regarding treatment regimens for bioﬁlm infections
e.g. ‘Please contact CML or infectious diseases specialist for
consultancy concerning treatment of the bioﬁlm infection’.
Q1-5 Should routine antibiotic susceptibility testing
employing planktonic bacteria from a bioﬁlm infection
be reported to the clinician? If yes—should the CML
add an explanation about the interpretation of the
results? How should such an explanation be written?
Routine antibiotic susceptibility testing—from disc diffusion to
microdilution-based automatic methods—are performed with
planktonically growing bacteria or Candida spp. and the break-
points, e.g. Susceptible, Intermediate and Resistant (S-I-R) based
on pharmacokinetics of the various antibiotics and the typical
minimum inhibitory concentrations (MIC) of the relevant mi-
croorganisms are given (EUCAST). Bioﬁlm-growing microor-
ganisms are signiﬁcantly more tolerant to antibiotics [6] and
corresponding breakpoints have not been established [34]. The S-
I-R results can therefore not be used to predict therapeutic
success in the case of bioﬁlm infections and offer no guide to
clinicians for treating such infections. However, bioﬁlm infections
are often foci for systemically spreading infections, e.g. blood-
stream infections originating from bioﬁlms in intravenous lines or
in urinary catheters or stents [110,111] (Fig. 5). Such systemic
spread of bioﬁlm infections can be treated successfully with an-
tibiotics based on the results of routine antibiotic susceptibility
testing, which should therefore be reported [112] (AIII). In that
case, routine antibiotic susceptibility testing can efﬁciently predict
treatment success or failure of the systemic infection (AII). Cli-
nicians should be informed by the CML that recurrence of the
infection from the bioﬁlm focus may occur if the focus cannot be
removed or suppressed by antimicrobial treatment. This may be
reported as, for example, ‘Please contact CML or infectious dis-
eases specialist for consultancy concerning treatment’ (AIII).
Q1-6 Are there any routine in vitro antibiotic
susceptibility tests that can reliably predict therapeutic
success?
Bioﬁlm susceptibility tests have been designed and include the
Calgary device, where bioﬁlms are grown on pegs protruding
from the lid of a microtitre plate which are subsequentlyious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
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their ‘bioﬁlm eradication concentrations’. However, such
testing has not yet resulted in reliable prediction of therapeutic
success [34,113–115] (DII).
Q1-7 Which research is urgently needed to improve
diagnosis of bioﬁlm infections?
 Algorithms for bioﬁlm diagnosis and for handling the samples
in the CML—why, when and how to demonstrate microbial
bioﬁlms.
 Improved non-invasive methods (e.g. image-based diagnostic
methods) for detecting bioﬁlms in vivo in patients.
 Host-speciﬁc markers that indicate a risk of bioﬁlm
infections.
 How many samples should be taken and for how long a
period.
 How should samples be analysed for the detection of
bioﬁlm-growing microorganisms that may be viable-but-
non-culturable in routine media.
 Which bacterial species play an active role in bioﬁlm
infections since culture-independent molecular methods
may identify a greater microbial diversity than previously
demonstrated by culture. To what extent do detected
species come from DNA released from non-viable bacteria?
 Will enzymatic (e.g. DNases or other compounds)
pretreatment of microbial bioﬁlms improve diagnostic and
therapeutic success?
 Characterization of bioﬁlm-speciﬁc antigens and detection
of speciﬁc antibodies against bioﬁlm-speciﬁc antigens.
 Standardized bioﬁlm susceptibility testing and establishment
of bioﬁlm-speciﬁc breakpoints for systemic and topically
administered antibiotics.
 Do some mycobacteria cause bioﬁlm infection in patients?
 Better animal models for relevant chronic bioﬁlm infections
[116].
 Assess the clinical impact of 16S rRNA gene detection in
intravenous catheters [73,117,118]
 Is there any evidence that ‘good bacteria’ reduce the
occurrence of bioﬁlm infection (prevention of bioﬁlm
infection by e.g. probiotics)?
 Development of methods for the diagnosis of CR-BSI relying
on the antigen-based detection of bioﬁlm formation inside
the catheter.
 Do surveillance cultures and light-microscopy studies of
accumulated mucus within the ETT have any beneﬁts on
early detection of ETT bioﬁlm formation and incidence of
VAP and therapeutic outcomes?Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobiologPrevention and Treatment of Bioﬁlm
InfectionsGenerally
Antibiotics are used for:
1) Prophylaxis i.e. to prevent infection in patients who are not
yet infected or colonized in, for example, the lungs or
bones/joints, if there is an unacceptable risk of
development of an infection in such organs during a
speciﬁc period or during a speciﬁc (e.g. surgical)
procedure; that means that the antibiotic penetrates the
site of a potential infection before the microorganisms
(e.g. surgical wound).
2) Pre-emptive treatment when colonization with a speciﬁc
microorganism is detected on, for example, mucosal
membranes and there is a known, unacceptable risk of
development of severe clinical infection with that
microorganism; that means that the antibiotic penetrates
the site of a potential infection after the microorganisms,
but before the establishment of an infection (e.g. pre-
emptive therapy after open bone fracture to prevent bioﬁlm
infection on osteosynthetic material or pre-emptive
eradication therapy of intermittent P. aeruginosa colonization
in the lungs of CF patients to prevent bioﬁlm infection).
3) Empiric treatment is based on the clinical diagnosis of
infection without knowledge of the microorganism but
covering the most probable microorganisms in a speciﬁc
clinical situation (e.g. staphylococci and E. coli in case of
CR-BSI).
4) Deﬁnitive treatment is based on clinical diagnosis and known
culture and susceptibility testing results.
These deﬁnitions are used in the following section.
Q2-1 Can systemic antibiotics (oral, intravenous) be
used to prevent some (which?) bioﬁlm infections? Can
the risk period be deﬁned?
Yes for some infections, not for other infections.
Short-term (surgery prophylaxis, some urinary
catheters) and intermediate-term (endotracheal tubes,
some CVCs, some urinary catheters)
Patients with infections related to their orthopaedic alloplastic de-
vices. Surgery-related bioﬁlm infections can be prevented (their
incidence reduced) by administration of prophylactic periop-
erative antibiotics (http://www.sign.ac.uk/pdf/sign104.pdf) [119]
(AI).y and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
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course systemic antibiotic therapy can postpone bioﬁlm in-
fections for up to 1–2 weeks [120,121], however we do not
recommend the use of antibiotic prophylaxis because of concern
about superinfection by multiresistant strains [17,18] (DIII).
No systemic antibiotics can be recommended for the pro-
phylaxis of CR-BSI [122–124] (DI).
There is no evidence to support the use of systemic anti-
microbial agents to prevent bioﬁlm infections in the treatment
of wound-associated infections [50,125,126] (CIII).
There is no regimen that can be recommended regarding
tissue ﬁllers at the present time [29].
Patients with endotracheal tube bioﬁlm VAP: Please see Q2-2.
Patients with intravenous catheters: see Antimicrobial lock
therapy.
Chronic disposing situation (CF, chronic wound, late alloplastic in-
fections, some CVCs (>1 year for, for example, parenteral feeding),
some urinary catheters, implants/ﬁllers (absorbable/material repair-
ing defects temporarily). Chronic P. aeruginosa lung infection in
CF cannot be prevented by prophylactic use of systemic anti-
biotics in patients before the onset of intermittent P. aeruginosa
colonization [33] (DI). Urinary tract infections in patients
chronically carrying urinary catheters cannot be prevented by
prophylactic use of systemic antibiotic. No information
currently exists about the other conditions.
Q2-2 Can topical use of antimicrobials or
antimicrobials attached to the surface of foreign bodies
(e.g. intravenous lines, urinary catheters, tracheal
tubes, artiﬁcial joints, bone cements for orthopaedic
surgery) be used to prevent some (which?) bioﬁlm
infections? Can the risk period be deﬁned?
Short term (surgery prophylaxis, some urinary catheters).
Orthopaedic alloplastics—There is good evidence to suggest that
antibiotic-impregnated materials (frequently gentamicin but also
tobramycin and vancomycin) reduce the incidence of
prosthesis-associated bioﬁlm infections [24,127,128] (AI).
Short-term urinary catheters—Coating with antimicrobials (e.g.
nitrofural) can only postpone but not prevent bioﬁlm infections
[29] (AI). Several studies conclude that the postponing effect is
sufﬁcient to prevent bioﬁlm infections in short-term catheter-
ization especially with nitrofurazone [120,131] (AI).
Intermediate or long-term (endotracheal tubes, some CVC, some
urinary catheters).
Endotracheal tube bioﬁlm (VAP)—A few studies [12,132] have
assessed the prophylactic effects of selective digestive decon-
tamination, which involves the oropharyngeal/gastric administra-
tion of topical non-absorbable antibiotics, on ETT bioﬁlm
formation. There is consistent evidence that selective digestiveClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectdecontamination does not inhibit ETT bioﬁlm formation, and we
do not suggest its use as a prophylactic strategy (DI). Nebulized
antibiotics achieve higher concentrations in the artiﬁcially venti-
lated airways (mean gentamicin concentration 1 h after nebuli-
zation of 80 mg was 790 μg/ml) than antibiotics administered by
the parenteral route and in one clinical study [133], the use of
nebulized gentamicin (80 mg in 4 ml saline every 8 h) in the pre-
vention of VAP has been tested and it was effective in preventing
the formation of ETT bioﬁlm by the most common causative
pathogens of VAP (CII). There have also been attempts to reduce
ETT bioﬁlm formation by coating the ETT surface with antimi-
crobial agents [63,134–136]. Among all the available antimicrobial
compounds used for ETT coating, silver (dispersion of silver-
sulphadiazine or micro-dispersed silver ions in a polymer) has
been the main focus in laboratory and clinical investigations
[44,134]. It has been shown that silver-coated ETTs could exert
antimicrobial effects within the proximal airways and hinder ETT
bioﬁlm formation. In addition, the silver-coated ETT exerted its
maximal effect during the ﬁrst 10 days of tracheal intubation
[44,136] and reduced mortality in patients with VAP [137,138]
and the cost of VAP [61]. We recommend the use of silver-
coated ETT in patients, who are expected to be ventilated for
longer periods of time (1 week) andwith risks for VAP (BI). The
Mucus Shaver (National Institutes of Health, Bethesda, MD, USA)
[61] has been devised to keep the ETT lumen free ofmucus and to
mechanically remove bioﬁlm. It comprises an inﬂatable balloon
with two or more 1.0-mm wide, 0.5-mm thick silicone rubber
‘shaving rings’. Theballoon is inﬂatedwith air inside the ETT lumen
sufﬁciently to force the two shaving rings ﬁrmly against the wall of
the ETT. Thereafter theMucus Shaver is gently retrieved followed
by resumption of ventilation. A clinical study [43] in a small pop-
ulation of patients showed that the Mucus Shaver is efﬁcient in
ETT bioﬁlm removal. In a recent study [46] in paediatric intubated
patients, ETT bioﬁlm was mechanically removed through the
inﬂatable balloonof a urethral catheter. This strategy reducedETT
bioﬁlm formation and incidence of clinically conﬁrmedVAP. Based
on the limited number of studies, we support the routine use of
dedicated devices to mechanically remove ETT bioﬁlm (BII).
Patients with CVCs—Use of chlorhexidine-impregnated sponges
or dressings reduces the incidence of CR-BSI and is considered
cost-effective [139–142] (AI). Coated CVCs should be
considered if the incidence of CR-BSI is still high after imple-
mentation of all preventive measures. In that case, minocycline/
rifampin-coated catheters are more efﬁcient than chlorhexi-
dine/silver sulphadiazine-coated catheters [143–146] (AI).
Preventive antibiotic lock technique—Antibiotic lock technique
(ALT) is done by application of a small volume of concentrated
antimicrobials, which is allowed to dwell for 12–24 h inside the
catheter lumen. The use of ALT as prophylaxis should be
restricted to patients who have experienced multiple CR-BSIious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
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more efﬁcient in reducing the rate of CR-BSIs in haemodialysis
patients than heparin locks [147,148]. Amixof taurolidine/citrate/
heparin gave a reduced rate of CR-BSI in haemodialysis patients
compared with heparin [149,150]. Use of taurolidine/citrate
without heparin is associatedwith an increased rate of thrombosis
of the catheter and thereby signiﬁcantly shorter catheter patency
in patients undergoing haemodialysis [151]. In paediatric cancer
patients, an early paper showed no signiﬁcant reduction of total
number of CR-BSI but a signiﬁcant reduction of CR-BSI due to
coagulase negative staphylococci with taurolidine/citrate
compared with heparin [152], whereas a more recent paper
showed a signiﬁcant reduction of CR-BSI with taurolidine/citrate
as compared with heparin if used from the time of insertion [153]
(BI). In high-risk patients receiving parenteral nutrition, taur-
olidine/citrate reduces the rate of CR-BSI when initiated after the
ﬁrst episode of CR-BSI compared with heparin [154] (BI).
Use of ethanol as ALT—No signiﬁcant reduction for ethanol 70%
compared with heparin in reduction of CR-BSI incidence in hae-
modialysis was observed [155]. Among immunosuppressed hae-
matology patients receiving chemotherapy, 70% ethanol
signiﬁcantly reduced CR-BSI compared with heparin in a ran-
domized study [156]. In cases of high-risk patients using in-home
parenteral nutrition (one previous CR-BSI), ethanol 70% was
assessed in a before–after study with a signiﬁcant reduction of CR-
BSI and need for catheter replacement in children [157]. However,
in a randomized placebo-controlled trial in adult haematology
patients, no signiﬁcant decrease in the incidence of CR-BSI and
more adverse effects were reported in the ethanol group [158].
Furthermore, it has been reported that ethanol could increase pre-
formed S. aureus bioﬁlm in vitro [159]. A recent meta-analysis
showed that ethanol was more effective than heparin lock to
reduce the incidence of CR-BSI and catheter replacement in pae-
diatric parenteral nutrition but may increase the risk of thrombosis
[160]. In conclusion we recommend the use of ethanol lock (CII).
Antibiotic/antiseptic ointments—The use of antibiotic ointments
that have limited antifungal activity may serve to increase
colonization and/or infection due to Candida species [161].
Regarding the prevention of fungal infections, the most
promising ALT includes use of amphotericin B, ethanol or
echinocandins [162]. (CII).
Indwelling urinary catheters—Coating with antimicrobials can
postpone bioﬁlm infections but not prevent them
[17,79,130,163] (CI).
Chronic disposing situation (e.g. CF, chronic wound, late alloplastic
infections, some CVC (>1 year for parenteral feeding, for example),
some urinary catheters, implants/ﬁllers (absorbable/material repair-
ing defects temporarily)). Chronic P. aeruginosa lung infection in
CF cannot be prevented by prophylactic use of nebulizedClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologantibiotics in patients before the onset of intermittent
P. aeruginosa colonization [33] (DI). Coating of long-term CVC
or coating of indwelling urinary catheters and urethral stents by
antibiotics or silver alloy cannot prevent chronic bioﬁlm
infection. The coating showed no or minimal effect on bioﬁlm
formation in several multicentre randomized controlled trials
and cannot be recommended for common use [129,163] (DI).
There is little information regarding tissue implants/ﬁllers
where local irrigation has been used [29] (CIII).
Q2-3 Can some bioﬁlm infections be prevented or early
bioﬁlm infections be eradicated by early antibiotic
treatment of colonization (no symptoms or signs) with
bacteria known to be able to cause bioﬁlm infections in
the type of patients in question?
Chronic P. aeruginosa lung infection in CF. The chronic infections
can be prevented by pre-emptive systemic and/or nebulized
antibiotic eradication therapy of intermittent P. aeruginosa
colonization of the lungs [31,34] (AI).
Patients with intravenous catheters. Yes, ALT in case of repeated
positive blood culture with identical coagulase-negative staph-
ylococci or other microbes from CVC but no clinical signs of
infection, also called CVC colonization [16,161] (CIII). There
are no data that point to preference of speciﬁc antimicrobial
agents.
Patients with VAP). No data available.
Patients with chronic wound infection. No data available.
Patients with infections related to their orthopaedic alloplastic de-
vices. No data available.
Patients with indwelling urinary catheters and urethral stents. No
data available.
Patients with infections connected to tissue ﬁllers, e.g. breast im-
plants. No data available.
Q2-4 Can some non-foreign-body-related bioﬁlm
infections be eradicated with antibiotics? Can some
foreign-body (e.g. artiﬁcial joints) related bioﬁlm
infections be eradicated with antibiotics without
removal of the foreign body? Can bioﬁlm infections in
critically important organs (e.g. lungs) or implants (e.g.
aortic grafts) be eradicated by antibiotics? Or rather
persistently suppressed by antibiotics? Are there any
methods to evaluate if the treatment is successful and
can be stopped?
Generally such bioﬁlm infections afﬂict patients who need from a
few weeks to life-long suppressive antibiotic treatment, ify and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
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of resistance due to conventional mechanisms (the risk is
reduced by combination therapy at least initially when the
number of microorganisms—and therefore risk of mutation— is
higher) and of adverse events caused by antibiotic treatment. It is
unknown which antibiotic concentration/dose is needed to
suppress bioﬁlm infection, whereas this is known in some dis-
eases regarding treatment of spreading planktonic microbial in-
fections originating from the bioﬁlm focus and thereby achieving
containment of the bioﬁlm infection (e.g. CF with chronic P.
aeruginosa lung infection which is a focal infection in localized
areas of the lungs). Currently only clinical signs and symptoms
and paraclinical tests (detection of the microorganisms by cul-
ture or culture-independent methods, imaging techniques, in-
ﬂammatory parameters) are available for evaluation of the effect
of antibiotic therapy. However, even if the surrogate parameters
indicate a favourable response, the microorganisms in the bioﬁlm
may survive and give rise to relapse in the case of cessation of
antibiotic therapy. Antibody levels may stabilize or decrease
slowly in the case of successful therapy, but are not a reliable
marker of successful treatment. Generally, there are no data
concerning when or if the chronic suppressive antibiotic therapy
can be stopped if the underlying condition is still present.
CF with chronic lung infections. Chronic P. aeruginosa lung infec-
tion can be eradicated in a few patients within the ﬁrst 1–2
years after the onset of the infection [31,34] (AII). This is not
possible in most cases of chronic lung infection. In these pa-
tients, chronic suppressive antibiotic therapy is given as daily
nebulized antibiotics combined with systemic antibiotics either
regularly every 3 months or at acute exacerbations and the
patients’ lung function can thereby be maintained for decades
[30,33,34] (AI).
Patients with infections related to their orthopaedic alloplastic devices
(e.g. joint prosthesis). Some foreign-body related bioﬁlm in-
fections can be eradicated with antibiotics without removal of
the foreign body, if duration of symptoms of infection is 3
weeks, implant is stable, there is an absence of sinus tract and
microorganisms are susceptible to suitable bioﬁlm-validated
antibiotics followed by debridement and antibiotic combina-
tion therapy, which includes an agent with efﬁcacy on bioﬁlms.
Rifampicins have this property against staphylococci and ﬂuo-
roquinolones have this property against Gram-negative bacilli,
but should be given as combination therapy with another
antibiotic due to the risk of development of resistance [164].
Antibiotic combination therapy has to be combined with initial
debridement surgery and exchange of modular parts of the
implant [37] and has proved to be more effective than mono-
therapy [165,25,128,166]. This strategy is recommended (AII).Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectPatients with intravenous catheters. Antimicrobial lock therapy is
recommended in case of uncomplicated CR-BSI caused by
coagulase-negative staphylococci, Enterobacteriaceae and
possibly P. aeruginosa [167–171] (AII). CR-BSI caused by
S. aureus should lead to catheter removal because of a high risk
of haematogenous complications, endocarditis and a low rate of
treatment success in case of ALT [169,171,172,173]. CR-BSI
caused by Candida spp. should also lead to catheter removal,
because non-removal is associated with an increased mortality
and a more prolonged candidaemia [16,102,162,175–182].
Even if catheter removal is recommended, many patients are
not candidates for catheter replacement because of their gen-
eral condition. The role of antifungal lock therapy against
Candida is not well deﬁned. Azoles have poor activity against
Candida bioﬁlms both in vitro and in vivo; lipid formulations of
amphotericin B are more effective than amphotericin B deox-
ycholate, and echinocandins have excellent activity
[161,182,183]. If conservative treatment with ALT is chosen,
clinical status and blood cultures should be monitored to detect
treatment failure, and therefore leading to catheter removal. In
cases of CR-BSI, systemic antibiotics should always be associ-
ated with ALT (AII).
Patients with endotracheal tube bioﬁlm and VAP. Systemic antibi-
otic therapy is not effective in clearing the bioﬁlm present on
the ETT [26] (DII). In patients with VAP, the pulmonary
infection is treatable when appropriate antibiotics guided by
microbiological ﬁndings are promptly administered [26] (AI).
The duration of therapy should be based upon the clinical
response. In the majority of cases, a 7-day treatment period is
appropriate. Nevertheless, in VAP caused by P. aeruginosa or
methicillin-resistant S. aureus, a longer treatment up to 14–21
days is preferable. It is recommended to reassess the clinical
response to therapy after 48–72 h and therapy should be
promptly changed in the case of lack of clinical improvement
[26] (AI).
Patients with indwelling urinary tract catheters or urethral stents.
Antibiotic therapy is not sufﬁcient to clear the bioﬁlm present
on the stent or catheter, but only decreases the number of
microorganisms in the urine and results in suppression of the
symptoms [174]. If the catheter is not removed or replaced,
relapse will probably occur after the end of treatment, there-
fore antibiotic treatment without removal of stent or catheter
cannot be recommended (AIII).
Patients with chronic wound infection. There is no reported evi-
dence to support the use of systemic antimicrobial agents in the
treatment of chronic wound-associated infections and their
healing, even if this therapeutic approach is quite common in
clinical practice [50,125,126] (CIII).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
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No data available.
Q2-5 What is the optimal antibiotic strategy for
treatment of established bioﬁlm infections?
Cystic ﬁbrosis. Chronic suppressive therapy with nebulized an-
tibiotics and systemic antibiotics either regularly every 3
months, or at acute exacerbations. Systemically administered
antibiotics yield concentrations in the respiratory compartment
of the lungs, which are adequate for planktonic bacteria,
although insufﬁcient for bioﬁlm-growing bacteria, whereas the
concentrations reached in the conductive compartment of the
lungs (bronchi, sputum) are low. Topically administered anti-
biotics by inhalation, on the other hand, provide very high
concentrations in the conductive compartment of the lungs, but
low concentrations in the respiratory compartment. Combi-
nations of systemic and topical antibiotics are therefore
frequently used to reach both the respiratory and the
conductive compartments of the lungs [30,31,33,34,184] (AI).
Pharmacokinetics/pharmacodynamics of antibiotics against
bioﬁlm-growing microorganisms has only been carried out in
animal studies and only with a few antibiotics, and the results
indicate that β-lactam antibiotics show time-dependent killing
and ciproﬂoxacin, colistin and tobramycin show concentration-
or dose-dependent killing of bioﬁlm-growing P. aeruginosa cells
similar to planktonic growing cells. However, the concentra-
tions of antibiotic needed were, in all cases, much higher even in
the case of antibiotics with time-dependent killing [185–187].
Patients with chronic wound infection. There is a lack of systematic
studies. There is a need to clarify when to treat (obvious signs
of infection versus low grade with few signs of infection) and
what to treat (e.g. which bacteria or fungi are pathogenic?). All
patients need non-antimicrobial strategies (e.g debridement,
compression, vacuum therapy etc.). If treatment is considered
necessary, combination therapy may be more effective (two
antibiotics with different mechanisms of action, systemic + local
treatment, antibiotic + local disinfectant). While the rationale
for debridement seems logical, the evidence to support its use
to enhance healing is scarce. There is more evidence in the
literature on the effectiveness of debridement for diabetic foot
ulcers than for venous ulcers and pressure ulcers. Additional
studies are needed to provide clinical evidence for debridement
inclusion in surgical treatment protocols for chronic wounds
[188] (BIII). After debridement, topical antimicrobial agents may
be more effective in the treatment of the infected wound and in
avoiding the re-establishing of microbial bioﬁlm [189] (BI).
Negative pressure wound therapy with irrigation or instillation
may lower the bacterial burden in chronic wounds and prevent
bioﬁlm formation (CIII).Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobiologPatients with infections related to their orthopaedic alloplastic de-
vices. There is probably a time-dependent success rate in the
case of implant retention. Based on observational studies,
critical timing is set at 3 weeks after start of symptoms (hae-
matogenous infections) or 4 weeks after implantation (periop-
erative infection) [37]. Debridement, implant retention and
long-term antimicrobial therapy in patients with acute in-
fections have a success rate of at least 85%. For these high cure
rates, treatment with active antibiotics (rifampicin against
staphylococci, ﬂuoroquinolones against Gram-negative bacilli) is
required [38]. In chronic infections (>3-week duration or >4
weeks after surgery), prosthetic devices should be replaced
[37] after thorough debridement. In the case of two-stage ex-
change, local therapy with an antibiotic-containing cement
spacer is generally used. In the case of one-stage exchange or
two-stage exchange with a short interval (2–3 weeks), long-
term antimicrobial therapy with suitable bioﬁlm-validated anti-
biotics should be used [190]. Duration of treatment is not well
established but a treatment period of 6–12 weeks is well
accepted (BIII). If the implant is not replaced before 2 months, 6
weeks of antimicrobial therapy is enough. No bioﬁlm-active
regimen is required after careful removal of all foreign mate-
rial (BII).
Patients with endotracheal tube bioﬁlm VAP. A detailed description
of adequate therapy in patients with VAP is beyond the scope of
these guidelines, and it is reported elsewhere [26]. Appropriate
and prompt antibiotic therapy signiﬁcantly improves survival for
patients with VAP. Importantly, antibiotics with good pulmo-
nary penetration should always be considered as ﬁrst-line
treatment. Antimicrobial selection should be based upon risk
factors for multidrug-resistant (MDR) pathogens. In patients at
risk for MDR pathogens, empiric broad-spectrum, multidrug
therapy is recommended. Therapy can be de-escalated as soon
as the causative pathogen is identiﬁed and antibiotic suscepti-
bility can be assessed. Combination therapy against Gram-
negative pathogens could provide a greater spectrum of activ-
ity and should be indicated based on the patient risks for MDR
pathogens and local prevalence of MDR pathogens. Addition-
ally, in institutions where methicillin-resistant S. aureus is
frequent, appropriate empiric antibiotic therapy should be
considered (AIII).
Patients with intravenous catheters. In the case of ALT performed
for bioﬁlm eradication, the length of treatment is between 7
and 14 days [169–171,191] (AII). There are no data that point
to preference of speciﬁc antimicrobial agents. Systemic antibi-
otics should always be associated with ALT in case of conser-
vative treatment (AII). Antibiotic concentration used for ALT
should be 100 to 1000-fold MIC [192]. Time of contacty and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
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data favours the adjunction of heparin to antibiotic. An in vivo
study demonstrated that heparin did not increase the effect of
vancomycin or ciproﬂoxacin effect in ALT [193].
Patients with indwelling urinary catheters or urethral stents. Use of
renally excreted antibiotics together with change of the cath-
eter or stent (AI). The recommended duration of the antibiotic
treatment is 7 days for patients with catheter-related urinary
tract infections who have prompt resolution of symptoms and
10–14 days for those with delayed response (AIII) [18].
Patients with infections connected to tissue ﬁllers e.g. breast implants.
No information available.
Q2-6 How can the treatment effect be monitored?
See Q2-1 to Q2-3. By clinical signs and symptoms and para-
clinical tests such as detection of microorganisms from samples
obtained from the focus of bioﬁlm infection by culture or
culture-independent methods, imaging techniques, inﬂamma-
tory parameters, improvement of organ function available for
evaluation of the effect of antibiotic therapy (e.g. lung function
measured by FEV1) [30,31,33,34]. However, even if the sur-
rogate parameters respond favourably, microorganisms in the
bioﬁlm may survive and give rise to relapse after cessation of
antibiotic therapy according to the experience from CF patients
with chronic P. aeruginosa bioﬁlm lung infection [30,31,33,34]
(AI). Antibodies may stabilize or decrease slowly in cases of
successful therapy, but this is not a reliable marker in that
respect. Generally, except in CF, where antibiotic therapy
(named chronic suppressive therapy or maintenance therapy) is
life-long in the case of chronic bioﬁlm infection [30,31,33,34]
(AI), there are no data concerning when or if the chronic
suppressive antibiotic therapy can be stopped if the underlying
condition is still present.
Q2-7 Which research is urgently needed to improve
prevention and treatment of bioﬁlm infections?
 New anti-bioﬁlm effective antibiotics and determination of
pharmacokinetics/pharmacodynamics for existing and new
anti-bioﬁlm antibiotics on young and old bioﬁlms including
combination antibiotic therapy.
 New anti-virulence drugs (for example drugs with quorum
sensing inhibiting properties) and determination of their
pharmacokinetics/pharmacodynamics on new and
established bioﬁlms including a combination of antibiotics
and anti-virulence drugs.
 Anti-inﬂammatory approaches (or modiﬁcation of
established approaches) for bioﬁlm infection therapy, sinceClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectiomuch of the tissue damage around bioﬁlm infections is due
to the host inﬂammatory response.
 Bioﬁlm matrix degrading or dissolving drugs such as
enzymes or chelators of components of bioﬁlms with the
purpose of rendering the bioﬁlm to a planktonic state,
amenable to antibiotic treatment.
 New combinations of antibiotics combined with bioﬁlm-
dissolving drugs.
 Topical antimicrobial treatment regimens.
 Combination of antimicrobials with ultrasound, electricity
or UV light.
 Leucopatch (local application of autologous
polymorphonuclear leucocytes and platelet-rich ﬁbrin) on
bioﬁlm infections in diseases with impaired circulation e.g.
infected chronic ulcers [194].
 Maggots (for selective debridement) in combination with
antimicrobials or quorum sensing inhibitors to treat
bioﬁlm infections in, for example, chronic ulcers.
 Vaccination with relevant bioﬁlm-forming bacteria to
prevent establishment of such infections inspired by the
moderate success in trials of P. aeruginosa vaccines against
chronic bioﬁlm infections in CF patients [195].
 Investigation of the period needed in vitro and in vivo to treat
bioﬁlms to achieve eradication (if possible) or permanent
suppression with the purpose of establishment of
standardized bioﬁlm treatment.
 Investigate the effects of dedicated devices to mechanically
remove ETT bioﬁlm, i.e. the Mucus Shaver, on the
prevention of VAP.
 Investigate therapeutic beneﬁts of nebulized antibiotics on
ETT bioﬁlm and VAP.
 Investigate how to monitor success of antibiotic treatment
of bioﬁlm infections.
 Establishment of animal models that realistically reﬂect
chronic bioﬁlm infections in humans.
 Investigate whether clinically relevant antimicrobial surfaces
can be developed for the long-term prevention of bioﬁlm
infections on medical foreign bodies (e.g. intravenous lines,
catheters, tracheal tubes, alloplastic materials).
 Since bioﬁlms are microaerophilic or anaerobic below their
surface and since the bactericidal activity of many antibiotics
involves reactive oxygen/hydroxyl species, the inﬂuence of
hyperbaric oxygen therapy on antibiotic treatment of
bioﬁlms should be studied.
 Assessment of new antibioﬁlm compounds against CR-BSI
such as ethanol and chelators.
 Evaluation of ALT in the clinical setting since data focusing
on the activity of antifungal agents and other biocides on
fungal bioﬁlms mainly correspond to in vitro or in vivo
(animal models) experiments.us Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, S1–S25
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